Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
{{output}}
This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquintinib in United States (U.S.) patients to confirm the recommended phase 2 dose (RP2D) established in China. Patients with advanced solid t... ...
